CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.